---
layout: minimal-medicine
title: Infliximab-dyyb
---

# Infliximab-dyyb
### Generic Name
Infliximab-dyyb

### Usage

Infliximab-dyyb is a biosimilar to Infliximab, a medication that blocks tumor necrosis factor-alpha (TNF-alpha), a protein involved in inflammation.  It's primarily used to treat several inflammatory conditions, including:

* **Crohn's disease:** A chronic inflammatory bowel disease affecting the digestive tract. Infliximab-dyyb helps reduce inflammation and improve symptoms like abdominal pain, diarrhea, and weight loss.
* **Ulcerative colitis:** Another chronic inflammatory bowel disease, specifically affecting the large intestine (colon) and rectum.  Similar to Crohn's disease, it aims to reduce inflammation and alleviate symptoms.
* **Rheumatoid arthritis:** A chronic autoimmune disease causing joint inflammation and pain. Infliximab-dyyb is used in combination with methotrexate to manage symptoms and slow disease progression.
* **Ankylosing spondylitis:** A type of arthritis primarily affecting the spine, causing inflammation and stiffness.
* **Psoriatic arthritis:**  Arthritis associated with psoriasis, an autoimmune skin condition.
* **Plaque psoriasis:** A chronic autoimmune skin condition characterized by raised, red, scaly patches on the skin. Infliximab-dyyb helps to clear these plaques and improve skin appearance.

It's important to note that while Infliximab-dyyb is a biosimilar to Infliximab, they are not interchangeable.  This means that switching between them requires medical supervision.


### Dosage

Infliximab-dyyb is administered intravenously (IV) over at least 2 hours.  Dosage varies depending on the specific condition being treated and the patient's weight.  The following are general guidelines, and precise dosages should always be determined and monitored by a healthcare professional:

**Adults:**

* **Induction Phase:** Usually involves multiple doses given over several weeks (e.g., weeks 0, 2, and 6). The dose is typically 3 mg/kg or 5 mg/kg depending on the condition.
* **Maintenance Phase:**  Following the induction phase, maintenance doses are given at intervals such as every 6 to 8 weeks.  Doses can vary between 3 mg/kg and 10 mg/kg depending on individual response and disease severity.

**Children (â‰¥6 years):**

Dosage for Crohn's disease and ulcerative colitis is similar to adults, typically starting with 5 mg/kg during the induction phase and continuing with maintenance doses every 8 weeks.  However, Infliximab-dyyb hasn't been studied extensively in children under 6 years of age.

**Dosage Adjustments:**  Dosage adjustments may be necessary based on individual patient response, adverse events, or other medical factors.  The need for adjustments should be determined by a healthcare professional.  Renal or hepatic impairment usually does not require dosage adjustments, but it's vital to be monitored closely by a physician.


### Side Effects

**Common Side Effects (occurring in more than 10% of patients):**

* Headache
* Abdominal pain
* Nausea
* Cough
* Pharyngitis (sore throat)
* Sinusitis
* Upper respiratory tract infections
* Infusion-related reactions (e.g., fever, chills, rash)


**Less Common but Serious Side Effects:**

* Serious infections (including tuberculosis, fungal infections, and sepsis)
* Allergic reactions (including anaphylaxis)
* Blood disorders (e.g., decreased white blood cell count)
* Heart problems (e.g., heart failure)
* Liver problems (e.g., hepatitis)
* Nervous system disorders (e.g., demyelinating diseases)
* Malignancies (e.g., lymphoma)


It's crucial to contact a healthcare provider immediately if any concerning side effects occur.


### How it Works

Infliximab-dyyb works by binding to and neutralizing TNF-alpha, a protein that plays a key role in the inflammation process. By blocking TNF-alpha's activity, Infliximab-dyyb reduces inflammation in the affected tissues, thereby alleviating symptoms and improving the condition in various inflammatory diseases.


### Precautions

* **Hypersensitivity:** Infliximab-dyyb is contraindicated in patients with hypersensitivity to Infliximab or its components.
* **Infections:**  Increased risk of serious infections, including tuberculosis. Patients should undergo testing for latent tuberculosis before starting treatment.  Live vaccines should be avoided.
* **Heart Failure:** Increased risk of worsening heart failure, particularly at higher doses.
* **Malignancies:** Increased risk of certain types of cancers, including lymphoma.
* **Pregnancy and Breastfeeding:**  Use during pregnancy should be carefully considered, and breastfeeding is generally not recommended.
* **Drug Interactions:**  Infliximab-dyyb can interact with other medications, particularly immunosuppressants.  It's essential to inform your doctor about all medications you are taking.
* **Other autoimmune conditions:**  Infliximab-dyyb may worsen existing autoimmune conditions, so patients with such conditions should be carefully monitored.

Always inform your healthcare provider about your medical history, including any current or past illnesses, allergies, and medications.


### FAQs

* **Q: How long does it take to see results?** A: The time it takes to see improvements varies depending on the condition and the individual. Some patients may experience improvements within a few weeks, while others may take longer.

* **Q: How long is the treatment course?** A: The treatment duration varies widely depending on individual response and disease severity. It may be ongoing for chronic conditions.

* **Q: Can I drink alcohol while taking Infliximab-dyyb?** A:  There's no definitive contraindication, but moderate alcohol consumption is advisable.  Excessive alcohol could potentially impact liver function, so moderation is key.  Consult your physician if you have concerns.

* **Q: How should I store Infliximab-dyyb?** A:  Follow the specific storage instructions provided by your pharmacist. It usually involves refrigeration.

* **Q: What should I do if I miss a dose?** A: Contact your healthcare provider for instructions. Don't attempt to make up for missed doses without guidance.

* **Q:  Is Infliximab-dyyb safe for long-term use?** A:  Long-term safety is monitored, but ongoing use is often necessary for chronic inflammatory conditions. The benefits and risks of long-term therapy should be discussed with your healthcare provider.  Regular monitoring is vital.

**Disclaimer:**  This information is for educational purposes only and does not constitute medical advice.  Always consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
